Intellia Therapeutics, Inc. $NTLA Shares Acquired by Royal Bank of Canada

Royal Bank of Canada lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 1,082.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 465,499 shares of the company’s stock after buying an additional 426,121 shares during the quarter. Royal Bank of Canada owned 0.33% of Intellia Therapeutics worth $5,968,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Quantinno Capital Management LP grew its position in Intellia Therapeutics by 18.7% in the first quarter. Quantinno Capital Management LP now owns 39,709 shares of the company’s stock valued at $509,000 after acquiring an additional 6,266 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Intellia Therapeutics during the first quarter valued at approximately $17,913,000. Sei Investments Co. lifted its position in shares of Intellia Therapeutics by 13.0% during the first quarter. Sei Investments Co. now owns 20,093 shares of the company’s stock worth $258,000 after purchasing an additional 2,316 shares in the last quarter. Cetera Investment Advisers lifted its position in shares of Intellia Therapeutics by 6.3% during the first quarter. Cetera Investment Advisers now owns 53,793 shares of the company’s stock worth $690,000 after purchasing an additional 3,192 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in Intellia Therapeutics by 36.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,552 shares of the company’s stock valued at $46,000 after purchasing an additional 948 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $12.02 on Wednesday. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -3.58 and a beta of 1.81. The company’s fifty day moving average price is $13.59 and its two-hundred day moving average price is $13.46.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). The company had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The company’s revenue was down 46.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.98) EPS. As a group, analysts anticipate that Intellia Therapeutics, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

NTLA has been the topic of several analyst reports. Chardan Capital lifted their price target on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Wall Street Zen downgraded Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Evercore raised Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 target price on the stock in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. Finally, Wolfe Research downgraded Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target for the company. in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Hold” and a consensus price target of $20.85.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.50% of the stock is currently owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.